Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium-Lactobacillus Triple Live Bacteria for SIBO/IMO and intestinal barrier in IBD
ChiCTR2500112578Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bifidobacterium-lactobacillus triple live bacteria in inflammatory bowel disease (IBD), autoimmune colitis, Crohn's disease and 2 more (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Cure rate of SIBO/IMO in IBD patients. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
bifidobacterium-lactobacillus triple live bacteria
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's diseaseblind loop syndrome (BLS)intestinal methanogen overgrowth (IMO)
Beyond the preview
Go deeper on ChiCTR2500112578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112578.